William J Sandborn

Summary

Affiliation: University of California
Country: USA

Publications

  1. doi request reprint Once-daily budesonide MMX® extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study
    William J Sandborn
    Division of Gastroenterology, University of California San Diego, 9500 Gilman Drive, La Jolla, California 92093 0956, USA
    Gastroenterology 143:1218-26.e1-2. 2012
  2. doi request reprint Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis
    William J Sandborn
    Division of Gastroenterology, University of California San Diego, La Jolla, California Electronic address
    Gastroenterology 146:85-95; quiz e14-5. 2014
  3. doi request reprint Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis
    William J Sandborn
    Division of Gastroenterology, University of California San Diego, La Jolla, California Electronic address
    Gastroenterology 146:96-109.e1. 2014
  4. ncbi request reprint Exploring the use of adalimumab for patients with moderate Crohn's disease: subanalyses from induction and maintenance trials
    William J Sandborn
    Division of Gastroenterology, University of California San Diego, La Jolla, CA, USA Electronic address
    J Crohns Colitis 7:958-67. 2013
  5. doi request reprint Vedolizumab as induction and maintenance therapy for Crohn's disease
    William J Sandborn
    Division of Gastroenterology, University of California, San Diego, La Jolla, CA 92093 0956, USA
    N Engl J Med 369:711-21. 2013
  6. doi request reprint Randomised clinical trial: the safety and tolerability of Trichuris suis ova in patients with Crohn's disease
    W J Sandborn
    Division of Gastroenterology, University of California San Diego, La Jolla, CA 92093 0956, USA
    Aliment Pharmacol Ther 38:255-63. 2013
  7. doi request reprint Association of baseline C-reactive protein and prior anti-tumor necrosis factor therapy with need for weekly dosing during maintenance therapy with adalimumab in patients with moderate to severe Crohn's disease
    W J Sandborn
    Division of Gastroenterology, University of California San Diego, La Jolla, CA 92093 0956, USA
    Curr Med Res Opin 29:483-93. 2013
  8. pmc Andrographis paniculata extract (HMPL-004) for active ulcerative colitis
    William J Sandborn
    University of California San Diego, La Jolla, CA 92093 0956, USA
    Am J Gastroenterol 108:90-8. 2013
  9. doi request reprint One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2
    W J Sandborn
    University of California San Diego, La Jolla, CA 92093 0956, USA
    Aliment Pharmacol Ther 37:204-13. 2013
  10. doi request reprint Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis
    William J Sandborn
    Division of Gastroenterology, University of California San Diego, 9500 Gilman Drive, La Jolla, California 92093 0063, USA
    Gastroenterology 142:257-65.e1-3. 2012

Collaborators

Detail Information

Publications52

  1. doi request reprint Once-daily budesonide MMX® extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study
    William J Sandborn
    Division of Gastroenterology, University of California San Diego, 9500 Gilman Drive, La Jolla, California 92093 0956, USA
    Gastroenterology 143:1218-26.e1-2. 2012
    ..Budesonide MMX® is a once-daily oral formulation of budesonide that extends budesonide release throughout the colon using multi-matrix system (MMX) technology...
  2. doi request reprint Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis
    William J Sandborn
    Division of Gastroenterology, University of California San Diego, La Jolla, California Electronic address
    Gastroenterology 146:85-95; quiz e14-5. 2014
    ..We evaluated subcutaneous golimumab induction therapy in TNF-α antagonist-naïve patients with moderate-to-severe UC despite conventional treatment...
  3. doi request reprint Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis
    William J Sandborn
    Division of Gastroenterology, University of California San Diego, La Jolla, California Electronic address
    Gastroenterology 146:96-109.e1. 2014
    ....
  4. ncbi request reprint Exploring the use of adalimumab for patients with moderate Crohn's disease: subanalyses from induction and maintenance trials
    William J Sandborn
    Division of Gastroenterology, University of California San Diego, La Jolla, CA, USA Electronic address
    J Crohns Colitis 7:958-67. 2013
    ..Anti-TNF agents are often reserved for patients with severe Crohn's disease (CD)...
  5. doi request reprint Vedolizumab as induction and maintenance therapy for Crohn's disease
    William J Sandborn
    Division of Gastroenterology, University of California, San Diego, La Jolla, CA 92093 0956, USA
    N Engl J Med 369:711-21. 2013
    ..The efficacy of vedolizumab, an α4β7 integrin antibody, in Crohn's disease is unknown...
  6. doi request reprint Randomised clinical trial: the safety and tolerability of Trichuris suis ova in patients with Crohn's disease
    W J Sandborn
    Division of Gastroenterology, University of California San Diego, La Jolla, CA 92093 0956, USA
    Aliment Pharmacol Ther 38:255-63. 2013
    ..Recent evidence suggests that embryonated eggs of the porcine whipworm Trichuris suis ova (TSO) may be an effective treatment for inflammatory bowel disease (IBD)...
  7. doi request reprint Association of baseline C-reactive protein and prior anti-tumor necrosis factor therapy with need for weekly dosing during maintenance therapy with adalimumab in patients with moderate to severe Crohn's disease
    W J Sandborn
    Division of Gastroenterology, University of California San Diego, La Jolla, CA 92093 0956, USA
    Curr Med Res Opin 29:483-93. 2013
    ....
  8. pmc Andrographis paniculata extract (HMPL-004) for active ulcerative colitis
    William J Sandborn
    University of California San Diego, La Jolla, CA 92093 0956, USA
    Am J Gastroenterol 108:90-8. 2013
    ..Andrographis paniculata has in vitro inhibitory activity against TNF-α, IL-1β and NF-κB. A pilot study of A. paniculata extract (HMPL-004) suggested similar efficacy to mesalamine for ulcerative colitis...
  9. doi request reprint One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2
    W J Sandborn
    University of California San Diego, La Jolla, CA 92093 0956, USA
    Aliment Pharmacol Ther 37:204-13. 2013
    ..Patients with moderately-to-severely active ulcerative colitis (UC) are unlikely to continue anti-TNF therapy in the absence of early therapeutic response...
  10. doi request reprint Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis
    William J Sandborn
    Division of Gastroenterology, University of California San Diego, 9500 Gilman Drive, La Jolla, California 92093 0063, USA
    Gastroenterology 142:257-65.e1-3. 2012
    ..Adalimumab is a fully human monoclonal antibody that binds tumor necrosis factor (TNF)-α. Its efficacy as maintenance therapy for patients with ulcerative colitis has not been studied in a controlled, double-blind trial...
  11. doi request reprint Ustekinumab induction and maintenance therapy in refractory Crohn's disease
    William J Sandborn
    Division of Gastroenterology, University of California San Diego, La Jolla, California 92093 0956, USA
    N Engl J Med 367:1519-28. 2012
    ..In patients with Crohn's disease, the efficacy of ustekinumab, a human monoclonal antibody against interleukin-12 and interleukin-23, is unknown...
  12. doi request reprint Abatacept for Crohn's disease and ulcerative colitis
    William J Sandborn
    Division of Gastroenterology, University of California San Diego, La Jolla, California, 92093 0956, USA
    Gastroenterology 143:62-69.e4. 2012
    ..The efficacy of abatacept, a selective costimulation modulator, in Crohn's disease (CD) and ulcerative colitis (UC) is unknown...
  13. doi request reprint Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis
    William J Sandborn
    Division of Gastroenterology, University of California San Diego, 9500 Gilman Dr, La Jolla, CA 92093 0956, USA
    N Engl J Med 367:616-24. 2012
    ..These cytokines are integral to lymphocyte activation, function, and proliferation...
  14. doi request reprint Certolizumab pegol for active Crohn's disease: a placebo-controlled, randomized trial
    William J Sandborn
    Division of Gastroenterology, University of California San Diego, La Jolla, 92093 0063, USA
    Clin Gastroenterol Hepatol 9:670-678.e3. 2011
    ..Certolizumab pegol (CZP) is a pegylated-conjugated Fab' against tumor necrosis factor (TNF). Additional data are needed regarding the efficacy of induction therapy with CZP in active Crohn's disease (CD)...
  15. doi request reprint Drug therapies and the risk of malignancy in Crohn's disease: results from the TREAT™ Registry
    Gary R Lichtenstein
    Division of Gastroenterology, Department of Medicine, Hospital of the University of Pennsylvania, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
    Am J Gastroenterol 109:212-23. 2014
    ..We assessed potential associations between malignancy and antitumor necrosis factor therapy in patients with Crohn's disease (CD), as this relationship is currently poorly defined...
  16. ncbi request reprint Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry
    Gary R Lichtenstein
    Department of Medicine, Division of Gastroenterology, Hospital of the University of Pennsylvania, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104 4283, USA
    Clin Gastroenterol Hepatol 4:621-30. 2006
    ..Long-term safety data for infliximab and other therapies in Crohn's disease (CD) are needed...
  17. doi request reprint Adverse events associated with common therapy regimens for moderate-to-severe Crohn's disease
    Josh Marehbian
    Health Benchmarks, Woodland Hills, California, USA
    Am J Gastroenterol 104:2524-33. 2009
    ..We sought to determine whether treatment with steroids, immunosuppressives (ISs), and anti-tumor necrosis factor (TNF) agents is associated with an increased risk of adverse events in patients with Crohn's disease (CD)...
  18. pmc A pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulator-treated adult patients with inflammatory bowel disease
    Gary R Lichtenstein
    Division of Gastroenterology, Hospital of the University of Pennsylvania, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Am J Gastroenterol 107:1051-63. 2012
    ..The objective of this study was to analyze the safety of long-term infliximab treatment, with/without concomitant immunomodulators, across Crohn's disease (CD) and ulcerative colitis (UC) clinical trials...
  19. pmc Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT™ registry
    Gary R Lichtenstein
    Division of Gastroenterology, Hospital of the University of Pennsylvania, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104 4283, USA
    Am J Gastroenterol 107:1409-22. 2012
    ..The objective of this study was to contribute long-term safety data for infliximab and other therapies in Crohn's disease (CD)...
  20. ncbi request reprint Predictive and protective factors associated with colorectal cancer in ulcerative colitis: A case-control study
    Fernando S Velayos
    Division of Gastroenterology and Hepatology, University of California San Francisco, San Francisco, California, USA
    Gastroenterology 130:1941-9. 2006
    ..The presence of postinflammatory pseudopolyps and use of other anti-inflammatory medications may be important variables that influence risk, but data are sparse...
  21. ncbi request reprint Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial
    Stephen B Hanauer
    Division of Gastroenterology, University of Chicago Medical Center, Illinois 60637, USA
    Gastroenterology 130:323-33; quiz 591. 2006
    ..A randomized, double-blind, placebo-controlled, dose-ranging trial was performed to evaluate the efficacy of adalimumab induction therapy in patients with CD...
  22. ncbi request reprint Positioning biologic therapy for Crohn's disease and ulcerative colitis
    Fernando S Velayos
    Center for Crohn s and Colitis, University of California, San Francisco, 2330 Post Street Suite 610, San Francisco, California 94115, USA
    Curr Gastroenterol Rep 9:521-7. 2007
    ....
  23. ncbi request reprint Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis
    Gary R Lichtenstein
    Division of Gastroenterology, University of Pennsylvania, Philadelphia, Pennsylvania 19104 4283, USA
    Clin Gastroenterol Hepatol 5:95-102. 2007
    ..We performed a randomized, double-blind, parallel-group, placebo-controlled, multicenter phase III study in patients with mild to moderately active ulcerative colitis...
  24. ncbi request reprint The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients
    Jean Frederic Colombel
    Division of Gastroenterology, Mayo Clinic, Rochester, MN 55905, USA
    Gastroenterology 126:19-31. 2004
    ..The aim of this study was to evaluate the short- and long-term safety of infliximab in patients with Crohn's disease in clinical practice...
  25. doi request reprint Management of Crohn's disease in adults
    Gary R Lichtenstein
    Department of Medicine, Division of Gastroenterology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
    Am J Gastroenterol 104:465-83; quiz 464, 484. 2009
    ..The final recommendations are based on the data available at the time of the production of the document and may be updated with pertinent scientific developments at a later time...
  26. ncbi request reprint Azathioprine or 6-mercaptopurine before colectomy for ulcerative colitis is not associated with increased postoperative complications
    Uma Mahadevan
    Division of Gastroenterology, University of California, San Francisco, USA
    Inflamm Bowel Dis 8:311-6. 2002
    ..To determine whether the use of azathioprine/6-mercaptopurine before colectomy is associated with an increased rate of postoperative complications...
  27. doi request reprint Changing Crohn's disease management: need for new goals and indices to prevent disability and improve quality of life
    Daniel Hommes
    Center for Inflammatory Bowel Diseases, UCLA Health System, Los Angeles, CA, USA
    J Crohns Colitis 6:S224-34. 2012
    ..These principles have been adopted for managing rheumatoid arthritis where there is now a focus on treat-to-target to achieve early remission. Lessons from rheumatoid arthritis can be translated to Crohn's disease...
  28. ncbi request reprint Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's disease
    Gary R Lichtenstein
    Division of Gastroenterology, Department of Medicine, Hospital of the University of Pennsylvania, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104 4283, USA
    Am J Gastroenterol 101:1030-8. 2006
    ..Theoretical concern exists that rapid luminal healing in Crohn's disease (CD) with therapies like infliximab increases the risk of intestinal stenosis, stricture, or obstruction (SSOs)...
  29. doi request reprint A test-based strategy is more cost effective than empiric dose escalation for patients with Crohn's disease who lose responsiveness to infliximab
    Fernando S Velayos
    Division of Gastroenterology and Hepatology, University of California, San Francisco, California 94115, USA
    Clin Gastroenterol Hepatol 11:654-66. 2013
    ..The comparative cost effectiveness of these 2 strategies is unknown. We investigated whether a testing-based strategy is more cost effective than an empiric dose-escalation strategy...
  30. doi request reprint Early use of immunosuppressives or TNF antagonists for the treatment of Crohn's disease: time for a change
    Ingrid Ordás
    Division of Gastroenterology, University of California San Diego, La Jolla, CA 92093 0063, USA
    Gut 60:1754-63. 2011
    ..Long-term prospective studies with robust outcomes are still needed to establish definitively the efficacy and safety of early combination therapy to prevent bowel damage, loss of gastrointestinal tract function and permanent disability...
  31. ncbi request reprint Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial
    Stephen B Hanauer
    Division of Gastroenterology, University of Chicago Medical Center, Chicago, Illinois 60637, USA
    Am J Gastroenterol 100:2478-85. 2005
    ..6 g/day. Whether 4.8 g/day of mesalamine (dosed with an investigational 800 mg tablet) is more effective than Asacol 2.4 g/day (dosed with a 400 mg tablet) in patients with moderately active ulcerative colitis is unknown...
  32. ncbi request reprint Pregnancy outcomes in women with inflammatory bowel disease: a large community-based study from Northern California
    Uma Mahadevan
    Division of Gastroenterology, Department of Medicine, University of California San Francisco, San Francisco, California 94115, USA
    Gastroenterology 133:1106-12. 2007
    ..The aim of this study was to determine whether pregnancy outcomes differ between women with and without inflammatory bowel disease (IBD) and to determine what risk factors adversely affect outcomes...
  33. ncbi request reprint Pneumocystis carinii pneumonia during maintenance anti-tumor necrosis factor-alpha therapy with infliximab for Crohn's disease
    Fernando S Velayos
    Division of Gastroenterology and Hepatology, University of California, San Francisco, California, USA
    Inflamm Bowel Dis 10:657-60. 2004
    ..Postmarketing surveillance through June of 2001 has identified 10 cases of PCP occurring during treatment with infliximab; 3 patients died...
  34. ncbi request reprint A systematic review of the measurement of endoscopic healing in ulcerative colitis clinical trials: recommendations and implications for future research
    Mark A Samaan
    Robarts Clinical Trials, Inc, London, ON, Canada Department of Gastroenterology, Academic Medical Center, Amsterdam, the Netherlands Department of Medicine, Division of Gastroenterology, King Abdulaziz University, Jeddah, Saudi Arabia Department of Epidemiology, McGill University, Montreal, QC, Canada Division of Gastroenterology, University of California, San Diego, La Jolla, California and Departments of Medicine, and Epidemiology and Biostatistics, Western University, London, ON, Canada
    Inflamm Bowel Dis 20:1465-71. 2014
    ....
  35. ncbi request reprint Endoscopic assessment and treating to target increase the likelihood of mucosal healing in patients with Crohn's disease
    Guillaume Bouguen
    Division of Gastroenterology, University of California San Diego, La Jolla, California Department of Gastroenterology, University Hospital of Rennes, Pontchaillou, France Inserm U991 University of Rennes 1, Rennes, France
    Clin Gastroenterol Hepatol 12:978-85. 2014
    ..We evaluated the feasibility of treating patients to achieve mucosal healing based on endoscopic evaluation (treating to target)...
  36. ncbi request reprint Outcomes of computed tomography and magnetic resonance enterography in clinical practice of inflammatory bowel disease
    Niraj S Patel
    Department of Medicine, University of California San Diego, La Jolla, CA, USA
    Dig Dis Sci 59:838-49. 2014
    ..Computed tomography (CT) and magnetic resonance (MR) enterography are now widely used to diagnose and monitor Crohn's disease...
  37. doi request reprint Ulcerative colitis
    Ingrid Ordás
    Division of Gastroenterology, University of California, San Diego, CA 92093 0956, USA
    Lancet 380:1606-19. 2012
    ..We provide practical therapeutic algorithms that are easily applicable in daily clinical practice, emphasising present controversies in treatment management and novel therapies...
  38. doi request reprint Cumulative incidence and risk factors for hospitalization and surgery in a population-based cohort of ulcerative colitis
    Sunil Samuel
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA
    Inflamm Bowel Dis 19:1858-66. 2013
    ..We sought to identify clinical and demographic features influencing hospitalization and colectomy in a population-based inception cohort of ulcerative colitis...
  39. ncbi request reprint Toward a personalized medicine approach to the management of inflammatory bowel disease
    Mahmoud H Mosli
    1 Department of Medicine, Division of Gastroenterology, Western University, London, Ontario, Canada 2 Robarts Clinical Trials, Robarts Research Institute, London, Ontario, Canada 3 Department of Medicine, Division of Gastroenterology, King Abdulaziz University, Jeddah, Saudi Arabia
    Am J Gastroenterol 109:994-1004. 2014
    ..This review discusses the current application of personalized medicine to the management of IBD. ..
  40. doi request reprint Feasibility of endoscopic assessment and treating to target to achieve mucosal healing in ulcerative colitis
    Guillaume Bouguen
    Division of Gastroenterology, University of California San Diego, San Diego, California and Department of Hepato Gastroenterology, University Hospital of Rennes, Pontchaillou, Inserm U991 University of Rennes 1, Rennes, France
    Inflamm Bowel Dis 20:231-9. 2014
    ..However, the feasibility and probability of reaching MH in clinical practice is unknown. We therefore evaluated the feasibility of "treating to target" according to endoscopic findings to reach MH...
  41. doi request reprint Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms
    Ingrid Ordás
    Division of Gastroenterology, University of California San Diego, La Jolla, California, USA
    Clin Pharmacol Ther 91:635-46. 2012
    ....
  42. doi request reprint Therapeutic drug monitoring in inflammatory bowel disease: current state and future perspectives
    Niels Vande Casteele
    Division of Gastroenterology, University of California San Diego, 9500 Gilman Dr 0956, La Jolla, CA, 92093, USA
    Curr Gastroenterol Rep 16:378. 2014
    ..While exploring the hypothesis that "one size does not fit all", we focused on the first prospective studies investigating the novel approach in IBD of 'target concentration adjusted dosing' and personalized medicine. ..
  43. ncbi request reprint Diagnosis and management of pouchitis
    Uma Mahadevan
    Department of Medicine, University of California, San Fancisco, USA
    Gastroenterology 124:1636-50. 2003
  44. doi request reprint Risk factors for lymphoma in patients with inflammatory bowel disease: a case-control study
    Waqqas Afif
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Inflamm Bowel Dis 19:1384-9. 2013
    ..Subgroups of patients with inflammatory bowel disease (IBD) may have an increased risk of developing lymphoma. We sought to identify factors that were associated with lymphoma in patients with IBD...
  45. doi request reprint The future of inflammatory bowel disease therapy: where do we go from here?
    William J Sandborn
    Inflammatory Bowel Disease Center, Division of Gastroenterology, University of California San Diego, La Jolla, CA 92093 0956, USA wsandborn ucsd edu
    Dig Dis 30:140-4. 2012
    ....
  46. ncbi request reprint Symptomatic overlap between microscopic colitis and irritable bowel syndrome: a prospective study
    Rami Abboud
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Inflamm Bowel Dis 19:550-3. 2013
    ..We sought to study this overlap in a prospective cohort...
  47. doi request reprint Cost-effectiveness of imaging strategies to reduce radiation-induced cancer risk in Crohn's disease
    Lauren E Cipriano
    Department of Management Science and Engineering, Stanford University, Stanford, California, USA
    Inflamm Bowel Dis 18:1240-8. 2012
    ....
  48. doi request reprint Histologic evaluation of ulcerative colitis: a systematic review of disease activity indices
    Mahmoud H Mosli
    Department of Medicine, Western University, London, Ontario, Canada Department of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia Department of Epidemiology and Biostatistics, McGill University, Montreal, Canada Robarts Clinical Trials, Inc, Robarts Research Institute, Western University, London, Ontario, Canada Department of Epidemiology and Biostatistics, Western University, London, Ontario, Canada Division of Gastroenterology, University of California San Diego, La Jolla, California Department of Gastroenterology, Academic Medical Center, Amsterdam, The Netherlands Pacific Rim Pathology Medical Corporation, San Diego, California Carolinas Medical Center, Charlotte, North Carolina Department of Pathology, Western University, London, Ontario, Canada and Department of Pathology, University Hospital of KU Leuven, Leuven, Belgium
    Inflamm Bowel Dis 20:564-75. 2014
    ..The aim of this study was to systematically review the existing histological indices for UC and assess their potential use in both patient management and clinical trials...
  49. ncbi request reprint Treatment of Crohn's disease with certolizumab pegol
    Trevor A Winter
    University of Kentucky, Division of Digestive Diseases and Nutrition, KY 40536 and Genentech Inc, 1DNA Way, South San Francisco, CA, USA
    Expert Rev Clin Immunol 3:683-94. 2007
    ..Certolizumab pegol will be a useful addition to the armamentarium of biologic agents that can be used for the long-term treatment of CD...
  50. ncbi request reprint Challenges in IBD Research: updating the scientific agendas
    Charles O Elson
    Division of Gastroenterology, Inflammatory Bowel Disease Center, University of Alabama at Birmingham, USA
    Inflamm Bowel Dis 9:137-53. 2003
  51. ncbi request reprint Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease
    Uma Mahadevan
    Division of Gastroenterology and Hepatology, University of California, San Francisco, 55905, USA
    Am J Gastroenterol 97:910-4. 2002
    ..Cyclooxygenase-2 inhibitors have fewer GI side effects than traditional NSAIDs in unselected patients. We report the safety of these agents in patients with IBD...
  52. doi request reprint Strategies for the care of adults hospitalized for active ulcerative colitis
    Suresh Pola
    Inflammatory Bowel Disease Center, Division of Gastroenterology, University of California San Diego Health System, La Jolla, CA, USA
    Clin Gastroenterol Hepatol 10:1315-1325.e4. 2012
    ..We review practical evidence-based management principles and propose a day-by-day algorithm for managing patients hospitalized for ulcerative colitis...